HOME >> BIOLOGY >> NEWS
Novel Method Of Gene Replacement Reported By University Of Washington Researchers

Dr. David W. Russell, assistant professor of medicine, and Roli Hirata, research technician at the University of Washington, report the successful use of a modified virus to perform a novel method of gene replacement that may be an important step toward overcoming obstacles to efficient gene therapy. Their findings are reported in the April issue of Nature Genetics.

Until now, gene therapy researchers have focused on gene addition, using a variety of modified viruses as vectors or transport vehicles to "infect" and insert the proper genetic material into cell nuclei that have genes with undesirable mutations. While the proper genetic material is inserted, it goes to random locations on the chromosome, and the faulty genetic material also remains.

By contrast, Russell and Hirata were able to achieve efficient gene correction. They succeeded in targeting the exact location of the mutated gene on the chromosome and replacing it with the correct genetic material present in the viral vector, at exactly the right location.

Russell uses a typewriter analogy: the new method finds the typographical error, whites it out and types in the proper sequence in the right place.

"If you had a 'typo' in a financial statement, say a missing zero, you'd want to fix in the right place, not randomly anywhere in the statement," he explains. "Or if you were correcting an instruction booklet with an error in it, you'd want to insert the corrected instruction in the right place on the right page."

The UW researchers' method guarantees that the new gene is controlled by appropriate genetic circuitry, ensuring that it is switched on in the right cells, at the right time and at the right dosage.

In addition to targeting exactly the right part of the cell, the repaired copy and the mutated copy of the genetic materal were exchanged at what researchers consider a very high frequency, in approximately 1 percent of ta
'"/>

Contact: Dr. David W. Russell
drussell@u.washington.edu
(206) 616-4562
University of Washington
30-Mar-1998


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:
(Date:4/1/2015)... Conn. , Apr. 1, 2015  NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... of Wocket smart wallets is underway to early access ... access group includes usage at retail outlets including Walmart, ... Pharmacy. Users report Wocket was accepted at all outlets ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
(Date:4/16/2015)... 2015 /CNW/ - Bioenterprise Corporation is pleased to announce that ... Charlottetown , PEI.  Bioenterprise has established a ... Council for the commercialization of agricultural technologies and innovations. ... PEI ADAPT.  They have been at the heart of ... explains Dave Smardon , President & CEO of ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)...  EMD Serono today announced the US biopharmaceutical ... , appointed Alise Reicin , MD, ... Development.  Dr. Reicin brings extensive research and early/late ... Immunology. She is an accomplished pharmaceutical executive with ... President in various capacities across R&D at MSD ...
(Date:4/16/2015)... Madison, NJ (PRWEB) April 16, 2015 ... recruited Dr. Joseph V. Gulfo to become the ... and Entrepreneurship. Simultaneously, FDU announced the kick-off of ... new program spearheaded by Dr. Gulfo, under the ... Silberman College of Business) and in collaboration with ...
Breaking Biology Technology:Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
Cached News: